Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5285)	12/30/2001 10:57:59 PM
From: Vector1	Read Replies (1) \| Respond to of 52153

Peter, it will certainly be an interesting conference call. Didn't SmithKline invest in Coulter about 6 months before its BLA was refused. Lets hope the problems are minor in nature. I think the drug has some efficacy so patients will be suffering while the FDA makes them wait. V1

To: Biomaven who wrote (5285)	12/31/2001 9:34:09 AM
From: Elmer	Respond to of 52153

Given the continued uncertainty in IMCL until the Co. meets with the FDA, I would think the stock drifts down for a while. The questions by the Goldman Sach analyst were right on. A new IRC may get a new conclusion on efficacy.

To: Biomaven who wrote (5285)	12/31/2001 10:16:04 AM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Peter, Looking at the chart for IMCL, siliconinvestor.com , if it breaks down below $40, there doesn't appear to be any support before the mid 20s. Would you still buy in the mid 30s? Am I dreaming that mid 20s may well be seen again???? Would you wait until after the January FDA meetings determine whether or not a further clinical trial will be needed to gather the additional data? Thanks, Ian P.S. Happy new year and best wishes to you as well as the many other contributors here.